• 相关企业梳理：1）中国生物制药：国内肝病治疗龙头企业， PPAR、FXR、FGF21、GLP-1、THR-β等NASH主流潜力靶点均有布局，拉尼兰诺 国内进度最快 ...

Novartis has joined with Allergan in a bid to get ahead in the race to get a drug approved to treat the fatty liver disease, non-alcoholic steatohepatitis (NASH). The Swiss pharma said it is to ...

But finding a drug that works against the disease has proved tricky: the FDA rejected Intercept Pharmaceuticals’ FXR agonist obeticholic acid in NASH in July after deciding its benefits would ...